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During the past 30 years, the endoscopic approach to benign biliary strictures (BBS) became the preferred “mini-invasive” treatment modality for
benign diseases. Endoscopic plastic or metallic stenting, and balloon dilation represent the gold standard treatment for BBS. Side-by-side insertion of
multiple plastic stents is a very effective treatment option for BBS following cholecystectomy or liver transplantation. This strategy has a low recur-
rence rate on long-term follow-up, with better results than fully covered self-expandable metal stents (FC-SEMS). FC-SEMS seems to have an advantage
and higher stricture resolution rate in patients with BBS secondary to chronic pancreatitis. Dilation of dominant biliary strictures in patients with
primary sclerosing cholangitis has a lower rate of infective complications than the stenting treatment. Endoscopic retrograde cholangiopancreatog-
raphy represents a safe and effective approach to BBS, with a very high success rate, especially when such cases are managed in a multidisciplinary
setting.
Copyright  2015, Society of Gastrointestinal Intervention. Published by Elsevier.
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Benign biliary strictures (BBS) can be classiﬁed as postoperative
and secondary to benign biliopancreatic diseases.
Postoperative biliary strictures can be related to an iatrogenic
injury following cholecystectomy or can occur at the biliary anas-
tomosis after liver transplantation. The most common diseases
leading to benign biliary strictures are chronic pancreatitis (CP) and
primary sclerosing cholangitis (PSC). Rare causes include portal
biliopathy, polyarteritis nodosa, radiofrequency ablation, radio-
therapy, and tuberculosis.
Endoscopic drainage of BBS is effective to restore bile ﬂow.
Multiple plastic stents insertion, and recently introduced fully
covered self-expandablemetal stents (FC-SEMS) can induce healing
of BBS, especially after cholecystectomy, liver transplantation, and
those secondary to CP. Endotherapy of PSC-related biliary strictures
can obtain temporary improvement of the biliary strictures but
chronic disease progression requires repeated treatments.
Endoscopic treatment of benign biliary strictures: plastic and
metal stents
Plastic stents
Plastic stents were used for the ﬁrst time in the late 1970s1,2 for
the endoscopic drainage of malignant biliary strictures. To date a
variety of plastic stents are available, and improvement ofDigestive Endoscopy Unit, Catholic University, Gemelli University Hospital, Rome, Italy
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possible plastic stent insertion in tight and angled strictures as in
the setting of BBS.
Plastic stents are available in different lengths (up to 18 cm) and
diameters [up to 11.5 French (Fr)]. They are usually tapered on one
end to facilitate negotiation of the strictures; 10 Fr is the preferred
diameter in BBS because it allows a good bile ﬂow and can be easily
pushed into the 4.2-mm working channel of the therapeutic
duodenoscope.
Straight stents are the standard design for biliary and pancreatic
indications. The choice of the stent depends on the bile duct
anatomy and stricture features. Straight stents are usually slightly
bent to conform to the anatomy of the biliary ducts. They may have
side holes for better drainage, and are provided with side ﬂaps to
avoid displacement and migration.
The choice of the stent length is related to the distance between
the proximal end of the stricture and the papilla of Vater, which can
be measured by graduated catheters.
The availability of different plastic stent size, shape, and diam-
eter permit to “tailor” the stent case by case, according to BBS
characteristics. Plastic stents make also possible the treatment of
postcholecystectomy BBS involving the main hepatic conﬂuence.
Materials
Three different polymers were used for biliary and pancreatic
stents: polyethylene, Teﬂon, and polyurethane.sity Hospital, Largo A. Gemelli 8, Rome, Italy.
vier. Open access under CC BY-NC-ND license.
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provided any deﬁnite advantage in terms of longer patency, when
compared to standard polyethylene stents in clinical practice.1,3–9
Polyethylene is the material most commonly used for plastic
stents.Plastic stents insertion
In the setting of BBS, the biliary sphincterotomy is recommended
to facilitate repeated stent exchange, insertion of multiple plastic
stents, and possible retreatment. Angle- or straight-tip fully hydro-
philic guidewires are recommended to negotiate tight BBS. Following
mechanical or balloon dilation, the plastic stent can be inserted.
Usually two or more plastic stents are placed side by side to dilate
BBS. A good coordination between operator and assistant is required
to place multiple plastic stents (MPS) and to avoid intrabiliary stent
migration; this fact does not represent a clinical problembecause bile
can ﬂow alongside the stents, but can make stent removal difﬁcult
during retreatments.Two or more plastic stents for BBS?
Dilation of BBS was attempted by insertion of two 10 Fr plastic
stents with planned exchange every 3 months for 1 year; at the
end of 1-year treatment stents were removed, but stricture
recurrence was high (20%).2 An “aggressive” approach to obtain a
progressive dilation of BBS was proposed in 200110 by insertion of
an increasing number of plastic stents every 3 months until
complete morphological stricture resolution; this approach lead
to an 11% stricture recurrence rate after a very long-term mean
follow-up of 13.7 years.11 The main limitation of plastic stenting
for BBS is the need for repeated endoscopic retrograde chol-
angiopancreatography (ERCP; usually 3–4) for a long period (at
least 1 year).Self-expandable metal stents
Self-expandable metal stents (SEMS) with a 30 Fr diameter,
were developed in the early 1990s. Uncovered SEMS ﬁnds an
indication in the setting of malignant biliary strictures, since are not
removable. FC-SEMS have an indication in BBS due to their
removability. A variety of SEMS are commercially available.
Most commonly used SEMS are made of a nickel-titanium alloy
(nitinol). Nitinol has at least two unique properties: shape-memory
and elasticity. Thermal shape-memory enables nitinol implants to
be compressed for insertion into small caliber delivery systems and
upon deployment in situ, at body temperature are restored to their
original shape. Elasticity is advantageous when ﬂexibility, con-
stancy of applied stress, and large expansion or deformation ratios
are needed. Because of this property, nitinol stents aremore ﬂexible
than stainless-steel SEMS. Nitinol is nonferromagnetic with a very
lowmagnetic susceptibility; thus, nitinol SEMS are compatiblewith
magnetic resonance imaging.Fully covered SEMS
SEMS with a plastic polymer covering were developed to
resolve the problem of tissue ingrowth and to allow removability
in the setting of BBS. SEMS covering membranes need to be
durable to ensure removability. Usually FC-SEMS have ﬂared
distal ends to reduce the risk of migration. FC-SEMS are available
in an 8- and 10- mm diameter and 4 cm, 6 cm, and 8 cm lengths.
No speciﬁc mesh design demonstrated to facilitate or impair
removability.Removability of FC-SEMS in the setting of postoperative biliary
strictures and chronic pancreatitis related biliary strictures was
evaluatedwith good results in several studies.12–20 Optimal time for
FC-SEMS removal is maybe between 4 months and 6 months, un-
less there are not enough data.Deployment
SEMS deployment is currently a standardized maneuver. SEMS
deployment does not usually require any previous stricture dila-
tion. SEMS introducers have a diameter varying from 8.5 Fr to 10 Fr,
like the standard plastic stents. In the delivery system, the SEMS are
constrained between an inner catheter (that allows the passage of
the guidewire) and an outer sheath. The delivery system is
advanced over the guidewire and positioned across the stricture.
Because some SEMS signiﬁcantly shorten after deployment, the
appropriate SEMS length should be evaluated on preliminary
cholangiography using appropriate graduated catheters.21 FC-SEMS
are released extending about 5–10 mm beyond the papilla into the
duodenum for an easier removability with foreign body forceps or
snares. After the delivery system is in position, the SEMS is released
by carefully pulling back the outer sheath. This maneuver must be
monitored by ﬂuoroscopy to permit minor adjustments of the
SEMS position before ﬁnal release. In case of erroneous placement
or inappropriate SEMS length, the stent can be reconstrained into
the delivery system before it has been totally deployed.
Postcholecystectomy biliary strictures
BBS following cholecystectomy were treated by complex sur-
gical repair with related morbidity and mortality11; a “mini-inva-
sive” endoscopic approach is advisable in patients with iatrogenic
lesions of the bile ducts10,22 (Fig. 1). Our experience with 164 pa-
tients treated with multiple plastic stents over a 22-year period
reported a 9.3% stricture recurrence rate after amean follow-up of 7
years; endoscopic retreatment of stricture recurrences was always
feasible and successful.
Postcholecystectomy strictures are short ﬁbrotic scars and are
typically located in the upper third of the common bile duct and can
involve the main hepatic conﬂuence. The bile duct below the
stricture is usually not dilated. These features may limit the use of
SEMS for a number of reasons. Correct positioning of partially
covered SEMS strictures near the hilum may be technically chal-
lenging, with possible damage to the normal mucosa of the
conﬂuence. SEMS tend to stretch the nondilated distal common bile
duct below the stricture, and this fact may have unpredictable
consequences on accurate positioning of a foreshortening stent.
Last, a high stent migration rate for FC-SEMS may limit its utility
when compared to progressive placement of plastic stents. Further
comparative studies with longer follow-up are needed before a ﬁrm
recommendation can be made in favor of either approach. It is also
noteworthy that SEMS removal may be technically challenging.23
Furthermore reported cases of postcholecystectomy biliary
strictures treated with FC-SEMS are very rare (Table 1).17,24–28
Anastomotic biliary strictures following liver transplantation
In the past decades biliary strictures following orthotopic liver
transplantation (OLT) were managed by surgical repair or percu-
taneous balloon dilation.29–31 More recently, ERCP and endoscopic
biliary plastic stent placement have been the primary therapeutic
approach for such lesions.32–38
Anastomotic strictures may occur at the level of any biliary
anastomosis, either duct-to-duct or hepatico-jejunostomy, in
Fig. 1. Postcholecystectomy biliary stricture before (A) and after (B) treatment with four plastic biliary stents.
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amenable for endoscopic treatment.
A characteristic of biliary strictures after OLT is that, also in the
case of tight strictures, the transplanted liver bile ducts do not
display the same degree of proportional dilation as non-
transplanted livers. This peculiar behavior of transplanted liver has
not been completely clariﬁed; however, the presence of ﬁbrosis
leading to less pliable ducts has been suggested as a possible eti-
ology.39 Nevertheless, the absence of substantial dilation for the
bile ducts may limit the number of stents to be placed side to side
for the initial dilation of the stenosis.
Pneumatic balloon dilation of anastomotic biliary strictures
without any stent placement is successful in < 50% of cases.40–42 In
a retrospective study on 25 biliary anastomotic strictures it was
found that clinically relevant stricture recurrences are more
frequent in a group of patients treated with balloon dilation only
(recurrence 62%) than in those treated with stents (recurrence rate
27%).42 Other authors found a single balloon stricture dilation
effective in 31% of the patients only, whereas 34.4% required moreTable 1 Endoscopic Therapy of Postoperative Biliary Strictures
Series of patients treated with fully covered removable metal stents
Study Etiology
Kahaleh et al, 200817 CP, stones, OLT, PO, AI
Mahajan et al, 200924 CP, stones, OLT, AI, PSC
Moon et al, 201225 CP, stones, OLT, PO, PSC, post- traumatic, vascular, pan
Tarantino et al, 201226 CP, stones, OLT, PO, PSC
Poley et al, 201227 CP, cholecystectomy, papillary stenosis
Devière et al, 201428 CP, cholecystectomy, OLT
AI, autoimmune pancreatitis; CP, chronic pancreatitis; OLT, orthotopic liver transplantatthan one session of balloon dilation and another third of the pa-
tients required stenting.41
Post-OLT anastomotic biliary strictures are usually dilated
with balloons (4–6 mm) followed by the placement of MPS
(Fig. 2). This approach appears to be successful with a durable
outcome.11,33,43,44 The majority of patients with anastomotic
biliary strictures after liver transplantation require several
endoscopic interventions. Recurrences have been variably re-
ported in about 7–13% of the cases for deceased donor living
transplantation after a 1–5-year mean follow-up; stenting of
anastomotic strictures is relatively easy when the whole liver has
been transplanted from a deceased donor, because the biliary
anastomosis is usually at the level of the middle common bile
duct, far from the main biliary conﬂuence. In the setting of living
donor-liver transplantation the biliary anastomosis is close to the
hilum and reported strictures recurrence is 21% after a 6-year
follow-up (Table 2).44–46
Anastomotic biliary strictures recurrence can be usually
managed conservatively by endoscopic restenting.Patients (n) Patients with postoperative
stricture (excluding OLT)
65 3
41 0
creatic cystic neoplasm 21 4
62 9
23 9
187 18
ion; PO, postoperative; PSC, primary sclerosing cholangitis.
Fig. 2. Anastomotic biliary stricture following liver transplantation (A) before and (B) after dilation with seven plastic stents.
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surveillance because strictures may recur after years from stent
removal. Long-term surveillance by liver function test monitoring
and bile ducts imaging is advisable. Some authors have observed
that anastomotic strictures diagnosed within 6 months after OLT,
usually have a better prognosis and good response to nonsurgical
therapy.33
FC-SEMS have been proposed to dilate anastomotic strictures
following OLT because their removability was safe and possible in
almost all cases; results are still under evaluation due to the high
incidence of stents migration and the high stricture recurrence rate
at the 2-year follow-up (Table 3).26,28,47,48
Biliary strictures secondary to chronic pancreatitis
Chronic pancreatitis (CP) is an inﬂammatory process charac-
terized by destruction of pancreatic parenchyma and ductal
structures with subsequent formation of ﬁbrosis.49 Strictures of the
common bile duct (CBD) can be found in 3–46% of patients with
advanced CP.50–57 The incidence of CP-related CBD stricture is
widely variable because not all patients present with jaundice,
which is also frequently transient.58
The nature of the stricture depends on the anatomical rela-
tionship of the CBD within the head of the pancreas. Fibrotic CBDTable 2 Endoscopic Therapy of Anastomotic Biliary Strictures Following Liver Trans
Results with multiple plastic stents
Study Patients (n) Mean of
ERCPs (n)
Mean
stent (n)
Morelli et al, 200845 38 3.5 2.5
Tabibian et al, 201044 69 4.1 NA
This study 62 3.3 4.2
Hsieh et al, 201346 38* 4 3
* All living donor transplantation.strictures occur as a consequence of recurrent acute inﬂamma-
tory state of the pancreas, which may ﬁnally result in a perma-
nent periductal ﬁbrotic invasion.59 CBD strictures can also be a
result of an acute inﬂammatory process of the pancreatic head, or
be secondary to a compression from a pancreatic pseudocyst.60 In
these two conditions the CBD stricture usually resolves after
healing of the acute inﬂammatory process or drainage of the
pseudocyst.
The clinical presentation varies from asymptomatic cholestasis
to symptomatic jaundice or cholangitis. In a small number of cases,
the stricture can lead during years to secondary biliary cirrhosis.61
Regression of liver ﬁbrosis was found by Hammel et al62 in patients
with CP-related CBD stricture after biliary drainage. The clinical
course of the disease is variable and usually characterized by ex-
acerbations and remissions.
CP-related CBD strictures are much more difﬁcult to dilate
compared to CBD strictures related to other benign causes.17,24 In
some clinical scenarios, CBD strictures due to CP may resolve with
time, but in the majority of patients they should be considered as
permanent. Sooner or later, any plastic stent will occlude, leading to
a recurrent sign of biliary obstruction and cholangitis. The real
indication to endoscopic plastic stent placement in these patients
should be carefully evaluated. The deﬁnitive therapy of CP-related
CBD strictures, especially in younger patients who presumablyplantation
Stenting
duration (mo)
Mean follow-up after
stent removal (y)
Stricture
recurrence (%)
3.6 1 13
15 1 8
10 5 7
5.3 6 21
Table 3 Endoscopic Therapy of Anastomotic Biliary Strictures Following Liver Transplantation
Results with fully covered removable metal stents
Study Patients (n) Median stenting
duration (mo)
SEMS
migration (%)
Success in
SEMS removal (%)
Stricture
resolution (%)
Stricture
recurrence (%)
Mean follow-up after
SEMS removal (mo)
Chaput et al, 201047 22 2 27 100 86 47 12
Hu et al, 201148 12 5 0 100 92 9 13
Tarantino et al, 201226 54 2 37 100 67 16 18
Devière et al, 201428 42 4–6 74 100 68 27 20
Andrea Tringali et al. / Benign biliary obstruction 5have a longer lifespan, is surgical drainage by Roux-en-Y hepatico-
jejunostomy.50,63
Endoscopic stenting of CBD strictures due to CP is indicated in
patients who are unﬁt for surgery because of severe comorbidities
or in those who refuse surgery. Endoscopic plastic stenting can also
be performed as a “bridge to surgery” in patients who refuse an
operation in the ﬁrst instance, or more often, in case of severe
jaundice, when surgery has to be delayed.
Despite the peribiliary ﬁbrosis, these strictures can be easily
passed with guidewire and guiding catheter. The placement of a 10
Fr or 11.5 Fr stent is not substantially difﬁcult and does not require
special skills. Pneumatic balloon dilation before stent placement is
seldom necessary.
Unfortunately, endoscopic treatment of these strictures with a
single plastic stent is effective only in the short term; in fact, the
long-term results are disappointing: almost 70% of the strictures
ineluctably recur after stent removal.64,65 The presence of calciﬁ-
cations in the pancreatic head parenchyma is associated with a
worse long-term prognosis.65,66
A prospective nonrandomized trial32 compared results of single
versus multiple plastic stents to dilate CP-related CBD strictures;
after a 4-year mean follow-up period, results were signiﬁcantly
better in the multiple stents group than in the single stent group
(92% vs. 24%, respectively; P < 0.01). Pozsár et al67 reported suc-
cessful outcomes at 1-year follow-up in 60% of the patients after
multiple plastic stenting for CP-related biliary strictures.
Despite the encouraging outcomes of some published papers,
endoscopic biliary plastic stenting, including multiple stent place-
ment, remains a marginal therapy for few selected patients with
chronic pancreatitis, who might better beneﬁt of a permanent
biliary drainage by surgery.
Results of FC-SEMS to dilate CP-related biliary strictures re-
ported satisfactory success in > 70% of the cases after a 2-year
follow-up (Table 4, Fig. 3).24,28,68–70 A recently published prospec-
tive trial conﬁrmed this promising result in a large cohort of 147
patients.28
Primary sclerosing cholangitis: Balloon dilation or stenting?
PSC is a chronic cholestatic hepatic disease characterized by
progressive ﬁbrosing inﬂammatory involvement of the intrahepaticTable 4 Bile Duct Strictures in Chronic Pancreatitis
Results with fully covered removable metal stents
Study N Stent design Median time to
SEMS removal (mo)
Stricture
at SEM
Cahen et al, 200868 6 FC-SEMS 5.5
Behm et al, 200969 20 PC-SEMS 5
Mahajan et al, 200924 19 FC-SEMS NA
Perri et al, 201270 7 UE-SEMS 6
10 FE-SEMS
Devière et al, 201428 127 FC-SEMS 11.3
FC, fully covered SEMS; FE, ﬂared ends stems; PC, partially covered SEMS; SEMS, self-exand extrahepatic bile ducts, leading to cholestasis and progressive
cirrhosis. No effective medical therapy has been found for this
disease, which sooner or laterwill cause end-stage liver disease and
need for transplantation. Endoscopy plays a role in the manage-
ment of patients with PSC, when they present with clinical and
biochemical deterioration and severe cholestasis, sustained by a
dominant biliary stricture involving the CBD or the right or left
main intrahepatic ducts.71
Current knowledge on endoscopic therapy of PSC is based on a
retrospective small series. Often in these patients, the choice of the
treatment is based more on local preferences and expertise than on
available evidence.
Dominant strictures in symptomatic patients may be treated by
balloon dilation or stents. Nevertheless, the real efﬁcacy of endo-
scopic stenting remains to be established, the effects of stenting on
patient survival are controversial and doubtful.
The gastroenterological community is divided in “stent sup-
porters” and “stent detractors”.72–76
In 1996, a European group73 reported on favorable outcomes in
25 patients treated by temporary stent placement. Endoscopic
stent placement was technically successful in 21/25 patients
(84%), with a median number of three procedures. Despite the
need for retreatment, prevalence of jaundice decreased from 62%
to 14%, pruritus from 52% to 5%, and fever from 38% to 10%.
Because of the high risk of stent clogging and complication rate,
the same group experimented with a protocol of stenting for a
very short time (mean 11 days). Two months after short-term
stent therapy, cholestatic complaints had improved in 83% of pa-
tients after a 35-month median follow-up, and at 1 year and 3
years 80% and 60% of patients, respectively, did not required
repeated treatments.77
More recently Gluck et al72 reported their experience with
endoscopic therapy on symptomatic PSC over a 20-year period.
Eighty-four patients with dominant strictures underwent 291 ERCP
for acute cholangitis unresponsive to antibiotic treatment, wors-
ening jaundice, pruritus, or pain. Of the 84 patients, 70% had
balloon dilations on one or more occasions; temporary stents were
placed in 51% of the patients. ERCP-related complications occurred
in 7.2% of procedures, and included pancreatitis in 3.4%, worsening
cholangitis in 1%, sepsis in 1% and in a minor percentage ductal
perforation, bleeding, and liver abscess.72resolution rate
S removal (%)
Migration
rate (%)
Complications (%) Median follow-up after
stent removal (mo)
67 33 67 20.5
80 5 4 22
58 5 16 NA
43 100 57 24
90 40 10
79 NA NA 20.3
pandable metal stents; UE, unﬂared ends SEMS.
Fig. 3. Chronic pancreatitis related biliary stricture (A) before and (B) after dilation with fully covered self-expandable metal stents.
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placement and balloon dilation in patients with PSC.74 In this study,
34 patients underwent endoscopic balloon dilation of the dominant
stricture (4- to 8-mm balloons) and 37 patients underwent endo-
scopic or percutaneous stent placement. Endoscopically placed
stents were exchanged every 3–4 months. Complications and
cholangitis were signiﬁcantly more common in the stent group
compared to the balloon dilation group and there were more
complications related to percutaneous than endoscopic stent
placement. However, there was no substantial difference between
the two groups with regard to cholestasis improvement and
symptoms resolution.74
Balloon dilation for the management of PSC-related dominant
strictures can be supported because it has a lower infective
complication rate than endoscopic stent placement, despite a
similar clinical beneﬁt.
Other authors reported on 500 balloon dilations and ﬁve stent
placements in 96 patients with dominant strictures, who were
followed for a median period of 7.1 years. ERCP-related complica-
tions were rare (pancreatitis 2.2%, acute cholangitis 1.4%, and bile
duct perforation 0.2%). Liver disease led to the need for OLT in 22.9%
of patients. Patient survival free of liver transplantation was 81%
after 5 years and 51% after 10 years.75
ERCP should be performed carefully and only when strictly
indicated in patients with PSC.76 Balloon dilation may be thepreferred therapeutic option due to the lower complications rate
than the stent insertion strategy.Conclusion
Postoperative strictures are effectively dilated by multiple plastic
stents. Results of FC-SEMS are promising for BBS secondary to
chronic pancreatitis. PSC-dominant strictures seems to have lower
infective complications after balloon dilatation than stent insertion.
Multiple plastic stenting has the advantage to obtain a persis-
tent biliary stricture dilation on long-term follow-up and permit
treatment of strictures involving the main hepatic conﬂuence, but
requires multiple procedures repeated over an extended period of
time, which is not patient friendly and is expensive.
FC-SEMS give the opportunity for stricture dilation in a shorter
time by two ERCPs only, but not all the strictures can be treated,
especially if located too close to the main hepatic conﬂuence
because of the risk of occlusion of the major intrahepatic ducts;
further long-term follow-up are not yet available.
Endoscopic approach to BBS is currently the ﬁrst-line approach
and needs to be “tailored” case by case.
A multidisciplinary evaluation (surgeon, gastroenterologist,
radiologist, and interventional radiologist) and detailed discussion
with the patient are the key aspects for a successful treatment.
Andrea Tringali et al. / Benign biliary obstruction 7Conﬂicts of interest
Vincenzo Bove, nothing to disclose.
Andrea Tringali had a consulting agreement for Boston Scientiﬁc
Corporation (Animal lab in 2012–2013, Speaking and teaching in
2014)
Guido Costamagna is a consultant for Olympus, Boston Scientiﬁc
Corporation, Cook Inc., Covidien and Taewoong Medical Inc.References
1. Landoni N, Wengrower D, Chopita N, Goldin E. Randomized prospective study
to compare the efﬁciency between standard plastic and polyurethane stents
in biliary tract malignant obstruction. Acta Gastroenterol Latinoam. 2000;30:
501–4.
2. Bergman JJ, Burgemeister L, Bruno MJ, Rauws EA, Gouma DJ, Tytgat GN, et al.
Long-term follow-up after biliary stent placement for postoperative bile duct
stenosis. Gastrointest Endosc. 2001;54:154–61.
3. Catalano MF, Geenen JE, Lehman GA, Siegel JH, Jacob L, McKinley MJ, et al.
“Tannenbaum” Teﬂon stents versus traditional polyethylene stents for treat-
ment of malignant biliary stricture. Gastrointest Endosc. 2002;55:354–8.
4. van Berkel AM, Boland C, Redekop WK, Bergman JJ, Groen AK, Tytgat GN, et al.
A prospective randomized trial of Teﬂon versus polyethylene stents for distal
malignant biliary obstruction. Endoscopy. 1998;30:681–6.
5. Terruzzi V, Comin U, De Grazia F, Toti GL, Zambelli A, Beretta S, et al. Pro-
spective randomized trial comparing Tannenbaum Teﬂon and standard poly-
ethylene stents in distal malignant biliary stenosis. Gastrointest Endosc. 2000;
51:23–7.
6. Schilling D, Rink G, Arnold JC, Benz C, Adamek HE, Jakobs R, et al. Prospective,
randomized, single-center trial comparing 3 different 10F plastic stents in
malignant mid and distal bile duct strictures. Gastrointest Endosc. 2003;58:54–8.
7. England RE, Martin DF, Morris J, Sheridan MB, Frost R, Freeman A, et al. A
prospective randomised multicentre trial comparing 10 Fr Teﬂon Tannenbaum
stents with 10 Fr polyethylene Cotton-Leung stents in patients with malignant
common duct strictures. Gut. 2000;46:395–400.
8. Barkun AN. A prospective randomised multicentre trial comparing 10F Teﬂon
Tannenbaum stents with 10F polyethylene Cotton-Leung stents in patients
with malignant common duct strictures. Gastrointest Endosc. 2001;53:399–
401.
9. van Berkel AM, Bruno MJ, Bergman JJ, van Deventer SJ, Tytgat GN, Huibregtse K.
A prospective randomized study of hydrophilic polymer-coated polyurethane
versus polyethylene stents in distal malignant biliary obstruction. Endoscopy.
2003;35:478–82.
10. Costamagna G, PandolﬁM, Mutignani M, Spada C, Perri V. Long-term results of
endoscopic management of postoperative bile duct strictures with increasing
numbers of stents. Gastrointest Endosc. 2001;54:162–8.
11. Costamagna G, Tringali A, Mutignani M, Perri V, Spada C, Pandolﬁ M, et al.
Endotherapy of postoperative biliary strictures with multiple stents: results
after more than 10 years of follow-up. Gastrointest Endosc. 2010;72:551–7.
12. Familiari P, Bulajic M, Mutignani M, Lee LS, Spera G, Spada C, et al. Endoscopic
removal of malfunctioning biliary self-expandable metallic stents. Gastrointest
Endosc. 2005;62:903–10.
13. O’Brien SM, Hatﬁeld AR, Craig PI, Williams SP. A 5-year follow-up of self-
expanding metal stents in the endoscopic management of patients with
benign bile duct strictures. Eur J Gastroenterol Hepatol. 1998;10:141–5.
14. Shin HP, Kim MH, Jung SW, Kim JC, Choi EK, Han J, et al. Endoscopic removal of
biliary self-expandable metallic stents: a prospective study. Endoscopy. 2006;
38:1250–5.
15. Kahaleh M, Tokar J, Le T, Yeaton P. Removal of self-expandable metallic
Wallstents. Gastrointest Endosc. 2004;60:640–4.
16. van Berkel AM, Cahen DL, van Westerloo DJ, Rauws EA, Huibregtse K, Bruno MJ.
Self-expanding metal stents in benign biliary strictures due to chronic
pancreatitis. Endoscopy. 2004;36:381–4.
17. Kahaleh M, Behm B, Clarke BW, Brock A, Shami VM, De La Rue SA, et al.
Temporary placement of covered self-expandable metal stents in benign
biliary strictures: a new paradigm? (with video). Gastrointest Endosc. 2008;67:
446–54.
18. Kahaleh M, Sundaram V, Condron SL, De La Rue SA, Hall JD, Tokar J, et al.
Temporary placement of covered self-expandable metallic stents in patients
with biliary leak: midterm evaluation of a pilot study. Gastrointest Endosc.
2007;66:52–9.
19. Eickhoff A, Jakobs R, Leonhardt A, Eickhoff JC, Riemann JF. Self-expandable
metal mesh stents for common bile duct stenosis in chronic pancreatitis:
retrospective evaluation of long-term follow-up and clinical outcome pilot
study. Z Gastroenterol. 2003;41:649–54.
20. Kahl S, Zimmermann S, Glasbrenner B, Pross M, Schulz HU, McNamara D, et al.
Treatment of benign biliary strictures in chronic pancreatitis by self-
expandable metal stents. Dig Dis. 2002;20:199–203.
21. Dumonceau JM, Devière J, Delhaye M, Baize M, Minet M, Cremer M. A guiding
catheter to facilitate accurate stent length determination. Gastrointest Endosc.
1998;48:203–6.22. Kuzela L, Oltman M, Sutka J, Hrcka R, Novotna T, Vavrecka A. Prospective
follow-up of patients with bile duct strictures secondary to laparoscopic cho-
lecystectomy, treated endoscopically with multiple stents. Hepatogastroenter-
ology. 2005;52:1357–61.
23. Tringali A, Blero D, Boskoski I, Familiari P, Perri V, Devière J, et al. Difﬁcult
removal of fully covered self expandable metal stents (SEMS) for benign biliary
strictures: the “SEMS in SEMS” technique. Dig Liver Dis. 2014;46:568–71.
24. Mahajan A, Ho H, Sauer B, Phillips MS, Shami VM, Ellen K, et al. Temporary
placement of fully covered self-expandable metal stents in benign biliary
strictures: midterm evaluation (with video). Gastrointest Endosc. 2009;70:
303–9.
25. Moon JH, Choi HJ, Koo HC, Han SH, Lee TH, Cho YD, et al. Feasibility of placing a
modiﬁed fully covered self-expandable metal stent above the papilla to
minimize stent-induced bile duct injury in patients with refractory benign
biliary strictures (with videos). Gastrointest Endosc. 2012;75:1080–5.
26. Tarantino I, Traina M, Mocciaro F, Barresi L, Curcio G, Di Pisa M, et al. Fully
covered metallic stents in biliary stenosis after orthotopic liver transplantation.
Endoscopy. 2012;44:246–50.
27. Poley JW, Cahen DL, Metselaar HJ, van Buuren HR, Kazemier G, van Eijck CH,
et al. A prospective group sequential study evaluating a new type of fully
covered self-expandable metal stent for the treatment of benign biliary stric-
tures (with video). Gastrointest Endosc. 2012;75:783–9.
28. Devière J, Nageshwar Reddy D, Püspök A, Ponchon T, Bruno MJ, Bourke MJ,
et al. Successful management of benign biliary strictures with fully covered
self-expanding metal stents. Gastroenterology. 2014;147:385–95.
29. Zajko AB, Campbell WL, Bron KM, Schade RR, Koneru B, Van Thiel DH. Diag-
nostic and interventional radiology in liver transplantation. Gastroenterol Clin
North Am. 1988;17:105–43.
30. Weber A, Prinz C, Gerngross C, Ludwig L, Huber W, Neu B, et al. Long-term
outcome of endoscopic and/or percutaneous transhepatic therapy in patients
with biliary stricture after orthotopic liver transplantation. J Gastroenterol.
2009;44:1195–202.
31. Colonna JO 2nd, Shaked A, Gomes AS, Colquhoun SD, Jurim O, McDiarmid SV,
et al. Biliary strictures complicating liver transplantation. Incidence, patho-
genesis, management, and outcome. Ann Surg. 1992;216:344–50.
32. Balderramo D, Navasa M, Cardenas A. Current management of biliary compli-
cations after liver transplantation: emphasis on endoscopic therapy. Gastro-
enterol Hepatol. 2011;34:107–15.
33. Williams ED, Draganov PV. Endoscopic management of biliary strictures after
liver transplantation. World J Gastroenterol. 2009;15:3725–33.
34. Londoño MC, Balderramo D, Cárdenas A. Management of biliary complications
after orthotopic liver transplantation: the role of endoscopy. World J Gastro-
enterol. 2008;14:493–7.
35. Graziadei IW, Schwaighofer H, Koch R, Nachbaur K, Koenigsrainer A,
Margreiter R, et al. Long-term outcome of endoscopic treatment of biliary
strictures after liver transplantation. Liver Transpl. 2006;12:718–25.
36. Verdonk RC, Buis CI, Porte RJ, Haagsma EB. Biliary complications after liver
transplantation: a review. Scand J Gastroenterol. 2006;243:89–101.
37. Thuluvath PJ, Pfau PR, Kimmey MB, Ginsberg GG. Biliary complications after
liver transplantation: the role of endoscopy. Endoscopy. 2005;37:857–63.
38. Pascher A, Neuhaus P. Bile duct complications after liver transplantation.
Transpl Int. 2005;18:627–42.
39. St Peter S, Rodriquez-Davalos MI, Rodriguez-Luna HM, Harrison EM, Moss AA,
Mulligan DC. Signiﬁcance of proximal biliary dilatation in patients with anas-
tomotic strictures after liver transplantation. Dig Dis Sci. 2004;49:1207–11.
40. Schwartz DA, Petersen BT, Poterucha JJ, Gostout CJ. Endoscopic therapy of
anastomotic bile duct strictures occurring after liver transplantation. Gastro-
intest Endosc. 2000;51:169–74.
41. Mahajani RV, Cotler SJ, Uzer MF. Efﬁcacy of endoscopic management of anas-
tomotic biliary strictures after hepatic transplantation. Endoscopy. 2000;32:
943–9.
42. Zoepf T, Maldonado-Lopez EJ, Hilgard P, Malago M, Broelsch CE, Treichel U,
et al. Balloon dilatation vs. balloon dilatation plus bile duct endoprostheses for
treatment of anastomotic biliary strictures after liver transplantation. Liver
Transpl. 2006;12:88–94.
43. Baron TH. Establishing a systematic endoscopic approach to the management
of anastomotic biliary strictures is needed. Liver Transpl. 2001;7:378–9.
44. Tabibian JH, Asham EH, Han S, Saab S, Tong MJ, Goldstein L, et al. Endoscopic
treatment of postorthotopic liver transplantation anastomotic biliary strictures
with maximal stent therapy (with video). Gastrointest Endosc. 2010;71:505–12.
45. Morelli G, Fazel A, Judah J, Pan JJ, Forsmark C, Draganov P. Rapid-sequence
endoscopic management of posttransplant anastomotic biliary strictures.
Gastrointest Endosc. 2008;67:879–85.
46. Hsieh TH, Mekeel KL, Crowell MD, Nguyen CC, Das A, Aqel BA, et al. Endoscopic
treatment of anastomotic biliary strictures after living donor liver trans-
plantation: outcomes after maximal stent therapy. Gastrointest Endosc. 2013;
77:47–54.
47. Chaput U, Scatton O, Bichard P, Ponchon T, Chryssostalis A, Gaudric M, et al.
Temporary placement of partially covered self-expandable metal stents for
anastomotic biliary strictures after liver transplantation: a prospective,
multicenter study. Gastrointest Endosc. 2010;72:1167–74.
48. Hu B, Gao DJ, Yu FH, Wang TT, Pan YM, Yang XM. Endoscopic stenting for post-
transplant biliary stricture: usefulness of a novel removable covered metal
stent. J Hepatobiliary Pancreat Sci. 2011;18:640–5.
Gastrointestinal Intervention 2015 4(1), 1–8849. Adler DG, Lichtenstein D, Baron TH, Davila R, Egan JV, Gan SL, et al. The role of
endoscopy in patients with chronic pancreatitis. Gastrointest Endosc. 2006;63:
933–7.
50. Petrozza JA, Dutta SK. The variable appearance of distal common bile duct
stenosis in chronic pancreatitis. J Clin Gastroenterol. 1985;7:447–50.
51. Sand JA, Nordback IH. Management of cholestasis in patients with chronic
pancreatitis: evaluation of a treatment protocol. Eur J Surg. 1995;161:587–92.
52. Wisløoff F, Jakobsen J, Osnes M. Stenosis of the common bile duct in chronic
pancreatitis. Br J Surg. 1982;69:52–4.
53. Afroudakis A, Kaplowitz N. Liver histopathology in chronic common bile duct
stenosis due to chronic alcoholic pancreatitis. Hepatology. 1981;1:65–72.
54. Aranha GV, Prinz RA, Freeark RJ, Greenlee HB. The spectrum of biliary tract
obstruction from chronic pancreatitis. Arch Surg. 1984;119:595–600.
55. Huizinga WK, Thomson SR, Spitaels JM, Simjee AE. Chronic pancreatitis with
biliary obstruction. Ann R Coll Surg Engl. 1992;74:119–23.
56. Stabile BE, Calabria R, Wilson SE, Passaro E Jr. Stricture of the common bile duct
from chronic pancreatitis. Surg Gynecol Obstet. 1987;165:121–6.
57. Yadegar J, Williams RA, Passaro E Jr, Wilson SE. Common duct stricture from
chronic pancreatitis. Arch Surg. 1980;115:582–6.
58. Scott J, Summerﬁeld JA, Elias E, Dick R, Sherlock S. Chronic pancreatitis: a cause
of cholestasis. Gut. 1977;18:196–201.
59. Sarles H, Sahel J. Cholestasis and lesions of the biliary tract in chronic
pancreatitis. Gut. 1978;19:851–7.
60. Delhaye M, Arvanitakis M, Bali M, Matos C, Devière J. Endoscopic therapy for
chronic pancreatitis. Scand J Surg. 2005;94:143–53.
61. Abdallah AA, Krige JE, Bornman PC. Biliary tract obstruction in chronic
pancreatitis. HPB (Oxford). 2007;9:421–8.
62. Hammel P, Couvelard A, O’Toole D, Ratouis A, Sauvanet A, Fléjou JF, et al.
Regression of liver ﬁbrosis after biliary drainage in patients with chronic
pancreatitis and stenosis of the common bile duct. N Engl J Med. 2001;344:
418–23.
63. Nealon WH, Urrutia F. Long-term follow-up after bilioenteric anastomosis for
benign bile duct stricture. Ann Surg. 1996;223:639–45.
64. Smits ME, Rauws EA, van Gulik TM, Gouma DJ, Tytgat GN, Huibregtse K. Long-
term results of endoscopic stenting and surgical drainage for biliary stricture
due to chronic pancreatitis. Br J Surg. 1996;83:764–8.
65. Kahl S, Zimmermann S, Genz I, Glasbrenner B, Pross M, Schulz HU, et al. Risk
factors for failure of endoscopic stenting of biliary strictures in chronicpancreatitis: a prospective follow-up study. Am J Gastroenterol. 2003;98:
2448–53.
66. Catalano MF, Linder JD, George S, Alcocer E, Geenen JE. Treatment of symp-
tomatic distal common bile duct stenosis secondary to chronic pancreatitis:
comparison of single vs. multiple simultaneous stents. Gastrointest Endosc.
2004;60:945–52.
67. Pozsár J, Sahin P, László F, Forró G, Topa L. Medium-term results of endoscopic
treatment of common bile duct strictures in chronic calcifying pancreatitis
with increasing numbers of stents. J Clin Gastroenterol. 2004;38:118–23.
68. Cahen DL, Rauws EA, Gouma DJ, Fockens P, Bruno MJ. Removable fully covered
self-expandable metal stents in the treatment of common bile duct strictures
due to chronic pancreatitis: a case series. Endoscopy. 2008;40:697–700.
69. Behm B, Brock A, Clarke BW, Ellen K, Northup PG, Dumonceau JM, et al.
Partially covered self-expandable metallic stents for benign biliary strictures
due to chronic pancreatitis. Endoscopy. 2009;41:547–51.
70. Perri V, Boskoski I, Tringali A, Familiari P, Mutignani M, Marmo R, et al. Fully
covered self-expandable metal stents in biliary strictures caused by chronic
pancreatitis not responding to plastic stenting: a prospective study with 2
years of follow-up. Gastrointest Endosc. 2012;75:1271–7.
71. Silveira MG, Lindor KD. Clinical features and management of primary scle-
rosing cholangitis. World J Gastroenterol. 2008;14:3338–49.
72. Gluck M, Cantone NR, Brandabur JJ, Patterson DJ, Bredfeldt JE, Kozarek RA. A
twenty-year experience with endoscopic therapy for symptomatic primary
sclerosing cholangitis. J Clin Gastroenterol. 2008;42:1032–9.
73. van Milligen de Wit AW, van Bracht J, Rauws EA, Jones EA, Tytgat GN, et al.
Endoscopic stent therapy for dominant extrahepatic bile duct strictures in
primary sclerosing cholangitis. Gastrointest Endosc. 1996;44:293–9.
74. Kaya M, Petersen BT, Angulo P, Baron TH, Andrews JC, Gostout CJ, et al. Balloon
dilation compared to stenting of dominant strictures in primary sclerosing
cholangitis. Am J Gastroenterol. 2001;96:1059–66.
75. Gotthardt DN, Rudolph G, Klöters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic
dilation of dominant stenoses in primary sclerosing cholangitis: outcome after
long-term treatment. Gastrointest Endosc. 2010;71:527–34.
76. Al-Kawas FH. Endoscopic management of primary sclerosing cholangitis: less is
better!. Am J Gastroenterol. 1999;94:2235–6.
77. Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four
years experience with short term stenting in primary sclerosing cholangitis.
Am J Gastroenterol. 1999;94:2403–7.
